Results 91 to 100 of about 24,471 (215)

Immunization Update, January 2009, Vol. 1, no. 10 [PDF]

, 2009
Monthly newsletter for the Iowa Department of Public ...

core  

The Update, March 22, 2010 [PDF]

, 2010
The Update is a bi-weekly web newsletter published by the Iowa Department of Public Health's Bureau of Family Health. It is posted the second and fourth week of every month, and provides useful job resource information for departmental health care ...

core  

The rise of companies from emerging markets in global health governance: opportunities and challenges [PDF]

, 2014
The article analyses the involvement of pharmaceutical companies from emerging markets in global health governance. It finds that they play a central role as low-cost suppliers of medicines and vaccines and, increasingly, new technologies.
ANNE ROEMER-MAHLER, Brooks, Brown, Buse, Chaudhuri, Clarke, Cooper Ramo, Drezner, Elbe, Fleury, Gold, Knight, Levy, Meyer, Petryna, Ramamurti, Roemer-Mahler, Schoofs, Wells, Whyte, Williams, Williamson, Youde, Zimmerman   +23 more
core   +1 more source

Unveiling New Aspects of Meningococcal Carriage and Disease Prevention. [PDF]

, 2015
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files.
Gottfredsson, Magnus
core   +1 more source

Rapid Recognition of Carfilzomib‐Induced Thrombotic Microangiopathy and Early Application of Eculizumab Successfully Rescued Two Relapsed Myeloma Patients

Chronic Diseases and Translational Medicine, Volume 12, Issue 1, Page 63-68, March 2026.
Zi Wang, Hua Zheng, Wei Wang, Xiaoxiao Shi, Yunpeng Wei, Chao Li, Junling Zhuang   +6 more
wiley   +1 more source

Prevention of Meningococcal Disease: Knowledge, Attitudes, and Practices of General Practitioners and Primary Care Pediatricians in South Italy

Vaccines
Background: The purpose of this study was to evaluate the knowledge, attitude, and current practices about prevention of meningococcal disease among general practitioners (GPs) and primary care pediatricians (PCPs) in Italy.
Silvia Angelillo, Concetta Paola Pelullo, Francesca Licata, Raffaele Lanzano, Francesco Napolitano, Gabriella Di Giuseppe   +5 more
doaj   +1 more source

Polyhydroxyalkanoate beads as a particulate vaccine against Streptococcus pneumoniae and Neisseria meningitidis : a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Microbiology at Massey University, Manawatu, New Zealand [PDF]

, 2017
Listed in 2018 Dean's List of Exceptional ThesesStreptococcus pneumoniae and Neisseria meningitidis are the major causes of pneumonia and meningitis, respectively, worldwide.
González Miró, Majela
core  

UK parents' attitudes towards meningococcal group B (MenB) vaccination: a qualitative analysis [PDF]

, 2017
OBJECTIVES: (1) To explore existing knowledge of, and attitudes, to group B meningococcal disease and serogroup B meningococcal (MenB) vaccine among parents of young children. (2) To seek views on their information needs.
Bedford, H, Jackson, C, Saliba, V, Yarwood, J   +3 more
core   +1 more source

Immunogenicity and safety of combined tetanus, reduced diphtheria, acellular pertussis vaccine when co-administered with quadrivalent meningococcal conjugate and human papillomavirus vaccines in healthy adolescents. [PDF]

, 2014
Objective: Current United States immunization recommendations for adolescents include vaccines against tetanus, diphtheria and pertussis (Tdap), human papillomavirus (HPV), and Neisseria meningitidis serogroups A, C, W-135, and Y. In this Phase IV study,
Alexanderian, David, Conversano, Michele, Garscadden, Alan, Gasparini, Roberto, Giglioli, Noemi, Han, Linda, Johnston, William, Percell, Sandra, Smolenov, Igor   +8 more
core   +1 more source

Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease

Canada Communicable Disease Report, 2020
Background: Trumenba™, a bivalent, factor-H binding protein meningococcal serogroup B (MenB-fHBP) vaccine was authorized for use in Canada in October 2017 for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis ...
Robyn Harrison, Robert Stirling, Oliver Baclic, Wendy Vaudry   +3 more
doaj   +1 more source